Brief Overview: We have initiated an investigation as to whether magnesium sulfate may be used as an opioid-sparing option for adjuvant analgesia in the pediatric intensive care unit, utilizing a high-dose infusion protocol developed based on literature review. It's analgesic plausibility is via NMDA-antagonism, though necessary dosing, blood levels, and regimens are not standardized and contain mixed results throughout the literature (both adults and pediatrics). This study is to establish feasibility for continued study and evolution of our protocol for use in critically ill children.

 

Disclosure: This abstract is built off preliminary data and is intended for submission only to the ISPP 2023 meeting. We do intend to streamline data in coming months for publication to help guide other developing studies with similar aims, however not anticipated to be complete by October.